21智讯1月13日电，康龙化成发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 161401.57万元—168574.98万元，同比预减6.00%—10.00%；预计2025年全年归属于上市公司股东的扣 除非经常性损益的净利润为150676.29万元—156215.86万元，同比预增36.00%—41.00%，变动原因为： 公司坚定地推行"全流程、一体化、国际化、多疗法"的核心战略，以客户需求为导向，深化全球化布 局，强化技术平台建设。2025年，公司预计营业收入同比增长13%—16%、归属于上市公司股东的扣除 非经常性损益后的净利润同比增长36%—41%、经调整的非《国际财务报告准则》下归属于上市公司股 东的净利润同比增长10%—15%。按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长 14.79%、归属于上市公司股东的扣除非经常性损益后的净利润同比增长54.09%、经调整的非《国际财 务报告准则》下归属于上市公司股东的净利润同比增长16.36%。如上所述，报告期内归属于上市公司 股东的非经常性损益为人民币11,000万元至人民币13,000万元；上年同期主要由于处置 PROT ...

康龙化成公告称，康龙化成预计2025年归属于上市公司股东的净利润为16.14亿元-16.86亿元，比上年同 期下降6%-10%。报告期内，公司营业收入同比增长13%-16%，扣除非经常性损益后的净利润同比增长 36%-41%。 （文章来源：第一财经） ...

康龙化成公告，预计2025年度净利润为16.14亿元–16.86亿元，同比下降6%–10%。预计营业收入为 138.72亿元–142.4亿元，同比增长13%–16%。预计归属于上市公司股东的扣除非经常性损益后的净利润 为15.07亿元–15.62亿元，同比增长36%–41%。 ...

证券代码：300759 证券简称：康龙化成 公告编号：2026-003 以下为本公司的 2025 年年度业绩预告。本业绩预告所载之财务数据未经审 计，除经调整的非《国际财务报告准则》下归属于上市公司股东的净利润或另 有注释外，本业绩预告所载之财务数据根据中国企业会计准则编制。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况：自愿性业绩预告 预计营业收入、归属于上市公司股东的扣除非经常性损益后的净利润以及经 调整的非《国际财务报告准则》下归属于上市公司股东的净利润同向上升，预计 归属于上市公司股东的净利润同向下降。 | 项 目 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | | 营业收入 | 营收：1,387,162.56 | 万元–1,423,989.89 万元 | 营收：1,227,577.49 万元 | | | 比上年同期增长：13%–16% | | | | 归属于上市公司股东 | 盈利：161,401.57 | 万元–168,574.98 万元 | 盈利：179,335.08 万元 | | ...

Core Viewpoint - The Hong Kong stock market saw a rise on January 13, 2026, with the Hang Seng Index increasing by 0.9%, driven by strong performance in the pharmaceutical sector, particularly by WuXi AppTec, which announced significant earnings growth [1] Group 1: Market Performance - The overall market exhibited a structural rally, with the pharmaceutical and biotechnology sectors showing active performance, particularly CRO concept stocks [1] - WuXi AppTec emerged as the leading stock among Hang Seng Index constituents, contributing significantly to the market's upward movement [1] Group 2: Company Performance - WuXi AppTec released a performance forecast on January 12, estimating a revenue of approximately 45.456 billion yuan for 2025, reflecting a year-on-year growth of about 15.84% [1] - The company anticipates a substantial increase in net profit attributable to shareholders, projected to reach 19.151 billion yuan, marking a year-on-year growth of approximately 102.65% [1] - The earnings growth is attributed to the company's integrated, end-to-end CRDMO business model and gains from the sale of stakes in joint ventures and divestiture of certain business segments [1] Group 3: Sector Trends - In addition to the pharmaceutical sector, gold stocks continued their recent upward trend, while some technology and commercial aerospace stocks experienced a pullback [1]

Core Insights - The medical services sector experienced a significant increase of 4.15% on January 13, with Norska leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Group 1: Stock Performance - Norska (301333) closed at 76.48, up 20.01% with a trading volume of 55,200 shares and a transaction value of 397 million yuan [1] - Yingsi (301257) also saw a rise of 20.00%, closing at 72.24 with a trading volume of 22,900 shares [1] - Hongbo Pharmaceutical (301230) increased by 20.00%, closing at 56.64 with a trading volume of 57,200 shares [1] - Lanwei Medical (301060) rose by 19.96%, closing at 13.28 with a trading volume of 135,210 shares [1] - Boji Pharmaceutical (300404) increased by 19.96%, closing at 12.92 with a trading volume of 627,100 shares [1] - Dian Diagnostics (300244) saw an increase of 11.90%, closing at 29.16 with a trading volume of 1,516,000 shares [1] Group 2: Capital Flow - The medical services sector saw a net inflow of 1.497 billion yuan from institutional investors, while retail investors experienced a net outflow of 713 million yuan [2] - The main stocks with significant capital flow include International Medical (000516) with a net inflow of 259 million yuan from institutional investors [3] - Boji Pharmaceutical (300404) had a net inflow of 243 million yuan from institutional investors, but also saw a net outflow of 140 million yuan from retail investors [3]

科网股表现分化，阿里巴巴、哔哩哔哩涨逾3%，阿里健康、零跑汽车等走高；商汤跌近5%，美的集 团、快手、华虹半导体均跌超2%。 编辑 ｜ 钉钉 1月13日，香港恒生指数收涨0.9%，恒生科技指数涨0.11%。 | 名称 | 现价 | 淵跌幅 ▼ | 淵跌 | | --- | --- | --- | --- | | 瑞科生物-B | 5.720 c | 37.50% | 1.560 | | 精优药业 | 0.099 c | 11.24% | 0.010 | | 直明最科-B | 6.730 c | 9.61% | 0.590 | | 药明康德 | 120,000 c | 8.30% | 9.200 | | 三济药业-B | 86.200 c | 8.29% | 6.600 | | 百興惠图-B | 42 760 c | 8.25% | 3.260 | | 泰格医药 | 53.500 c | 8.17% | 4.040 | | 荣昌生物 | 100.100 c | 7.87% | 7.300 | | 复宏汉霖 | 68.750 c | 6.42% | 4.150 | | 药明目信-B | 2.950 c | 6.1 ...

Group 1 - The core viewpoint of the news is that the Taikang Medical Health Fund has experienced significant declines in its stock performance for both Class C and Class A shares, with decreases of 13.45% and 13.02% respectively in 2025 [1][2] - The top ten holdings of the fund as of the third quarter of 2025 include companies such as Jingtai Holdings, Kanglong Chemical, Fangzhou Jianke, Sanofi Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [1] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., Ltd. and has been with Taikang since July 2019, becoming the fund manager on March 8, 2022 [1]

Investment Rating - The report indicates a positive outlook for WuXi Biologics, suggesting that the company will outperform its peers in the biopharmaceutical CDMO sector in 2026 [5]. Core Insights - WuXi Biologics is expected to experience a reacceleration in growth in 2026, driven by three main catalysts: the growth momentum from dual/multi-antibody projects, a strong project intake in 2025 with a net addition of 128 projects, and a reduction in valuation pressure from geopolitical factors [5][8]. - The non-XDC business of WuXi Biologics is anticipated to accelerate in 2026, contrary to market expectations, returning the company to a multi-engine growth trajectory [6]. - The company’s dual/multi-antibody projects are projected to be a significant growth driver, with a 30% year-on-year increase in project numbers for 2025, outpacing the overall company growth rate of 16% [7]. Summary by Sections Company Overview - WuXi Biologics is a leading global contract research, development, and manufacturing organization (CRDMO) that provides end-to-end solutions to help partners develop biopharmaceuticals from concept to commercialization [10]. Financial Performance - As of January 9, 2026, the stock price is HKD 37.06, with a market capitalization of USD 19.65 billion. The average daily trading volume over the past three months is USD 138.43 million [13]. - The revenue breakdown shows that biopharmaceuticals account for 88.8% of total revenue, while WuXi XDC contributes 11.2% [11]. Growth Drivers - The report highlights that the strong project intake in 2025, with 128 new projects, sets a solid foundation for faster growth in 2026 compared to 2025 [5][8]. - The profitability outlook is favorable due to the optimization of the project structure towards complex dual/multi-antibody projects, which is expected to enhance profit margins [7].

Market Overview - The A-share market experienced a collective decline on January 13, with the Shanghai Composite Index closing at 4163.84 points, down 0.03%, the Shenzhen Component Index down 0.31%, and the ChiNext Index down 0.83% [2] - A total of 2427 stocks rose while 2862 stocks fell, indicating a mixed market sentiment [4] Sector Performance - The healthcare services, lithium mining, precious metals, and insurance sectors showed notable gains, while sectors such as commercial aerospace, communication equipment, and shipbuilding faced declines [4] - The healthcare services sector rose by 6.61%, lithium mining by 4.86%, and precious metals by 3.91% [5] Lithium Mining Sector - Lithium mining stocks surged, with major players like Tibet Summit hitting the daily limit, and companies such as Salt Lake Industry and Ganfeng Lithium rising over 7% [13] - The price of lithium carbonate futures on the Shanghai Futures Exchange surpassed 170,000 yuan per ton, marking a rise of over 9% and reaching a new high since October 2023 [7] Insurance Sector - The insurance sector showed resilience, with China Life Insurance rising over 3% to a market value of 1,279.4 billion yuan, and Ping An Insurance increasing over 2% to a market value of 1,203.4 billion yuan [10][12] - A report from Guojin Securities predicts that new insurance premiums for listed companies will achieve double-digit growth by 2026, driven by the bancassurance channel and increased market share of large insurers [15] AI Healthcare Sector - AI healthcare stocks experienced significant activity, with companies like Di'an Diagnostics and Nossger hitting the daily limit, and others like Meien Health and International Medicine also seeing substantial gains [16] - Nvidia announced a joint investment of $1 billion with Eli Lilly to establish an AI drug laboratory, aiming to accelerate medical discoveries [18] Precious Metals Sector - The precious metals sector saw a rise, with spot gold prices reaching a record high of $4630.28 per ounce [20] - Stocks such as Hunan Silver and Xiaocheng Technology rose over 8%, while other companies like Shandong Gold and Zhongjin Gold also experienced gains [21]